It has been shown that tumor necrosis factor receptor-2 (TNFR2) stimulation leads to degradation of TNF receptor associated factor-2 (TRAF2) and inhibition of TNFR1-induced activation of NFjB and JNK. Here, we show that TRAF1 inhibits TNFR2-induced proteasomal degradation of TRAF2 and relieves TNFR1-induced activation of NFjB from the inhibitory effect of TNFR2. TRAF1 co-recruited with TRAF2 to both TNF receptors. Despite lacking an amino-terminal RING/zinc-finger domain, TRAF1 did not interfere with TNFR1-induced activation of JNK and NFjB. It is noted that physiological expression levels of TRAF1 enhanced NFjB activation and interleukin-8 (IL8) production induced by TNFR2. Thus, TRAF1 shifts the quality of integrated TNFR1-TNFR2 signaling from apoptosis induction to proinflammatory NFjB signaling.
Introduction
The pleiotropic cytokine tumor necrosis factor (TNF) is the prototypic member of the TNF ligand family. TNF is initially expressed as a trimeric type II transmembrane protein (memTNF) from which a soluble variant (sTNF) can be released on proteolytic processing . Transmembrane TNF, as well as sTNF, is able to bind to TNFR1 and TNFR2, two typical members of the TNF receptor superfamily . Importantly, memTNF potently stimulates intracellular signaling through both TNF receptors, whereas sTNF predominantly triggers TNFR1-associated signaling pathways . Thus, ligand binding is not necessarily sufficient for TNFR2 activation. TNFR1 belongs to the death receptor subgroup of the TNF receptor superfamily and interacts with the death domain-containing serine/ threonine kinase RIP (receptor-interacting protein) and the death domain-containing adaptor protein TRADD (Wajant, 2003; Wajant et al., 2003) . The latter indirectly recruits TNF receptor-associated factor-2 (TRAF2), which belongs to the TRAF family of adapter proteins, and the TRAF2-associated proteins cIAP1 and cIAP2 into the TNFR1 signaling complex (Wajant et al., 2001) . By currently poorly understood mechanisms RIP mediates TNFR1-induced necrotic cell death. Concomitantly with ligand-induced TNFR1 internalization, RIP, TRADD, TRAF2 and the cIAP proteins are released and form together with the death domaincontaining adaptor protein FADD and the FADDinteracting proteins procaspase-8 and FLIP the cytosolic complex II. Under conditions of insufficient availability of the antiapoptotic cIAP and FLIP proteins, complex II triggers caspase-8 activation and apoptotic cell death (Muppidi et al., 2004) . It is noted that RIP and TRADD are also involved in TNFR1-mediated activation of the NFkB pathway, which regulates numerous survival genes encoding antiapoptotic proteins, such as FLIP, cIAP2, XIAP and Bcl2. Transcriptional upregulation of manganese superoxide dismutase and ferritin heavy chain protects cells further from reactive oxygen species-mediated necrosis (Wong and Goeddel, 1988; Jones et al., 1997; Wajant et al., 2003; Pham et al., 2004) . As a consequence, TNFR1-induced cell death normally only occurs on blockage of the NFkB pathway.
TNFR2 contains no death domain and interacts with TRAF2 through a short TRAF-interacting motif (Wajant et al., 2001 . Although TRAF2 has been crucially implicated in stimulation of NFkB and mitogen-activated protein kinase cascades by various members of the TNF receptor superfamily including TNFR1, its relevance for TNFR2-induced signaling is unclear. TNFR2 stimulation results in recruitment of TRAF2 into a triton X-100-insoluble compartment (Chan and Lenardo, 2000; Fotin-Mleczek et al., 2002; Li et al., 2002; Wu et al., 2005) . The TRAF2-associated E3 ligase cIAP1 can then interact with the E2 protein Ubc6, which stimulates the E3 activity of cIAP1 leading to ubiquitination and proteasomal degradation of TRAF2 (Chan and Lenardo, 2000; Li et al., 2002; Wu et al., 2005) . The resulting depletion of cytoplasmic TRAF2/cIAP1/2 complexes has been implicated in TNFR2-mediated enhancement of TNFR1-induced apoptosis (Wang et al., 1998; Chan and Lenardo, 2000; Fotin-Mleczek et al., 2002; Li et al., 2002; Wu et al., 2005) . In fact, enhancement of TNFR1-induced apoptosis by costimulation of TNFR2, which has been observed in several cellular models, depends on the integrity of the TRAF-binding site of TNFR2 (Weiss et al., 1997; Declercq et al., 1998) . Furthermore, TNFR2-induced depletion of cytoplasmic TRAF2 coincidences with inhibition of TNFR1-induced activation of c-Jun NH2-terminal kinase (JNK) and NFkB, two responses crucially dependent on TRAF2 Wajant et al., 2003) . It is noted that TNFR2-induced TRAF2 depletion can act in concert with induction of endogenous memTNF by TNFR1 or TNFR2 leading to apoptosis after exclusive TNFR2 stimulation or to an unusual transcription-dependent mode of TNFR1-induced apoptosis (Vercammen et al., 1995; Grell et al., 1999; Weingartner et al., 2002) . In the latter case, TNFR1-induced apoptosis relies on the induction of memTNF and subsequent stimulation of TNFR2-mediated TRAF2 depletion, resulting in sensitization for TNFR1-induced apoptosis (Weingartner et al., 2002) . Apoptosis induction by TNFR2 and other non-death receptors of the TNF receptor family, in turn, can be caused by the induction of endogenous TNF that subsequently triggers apoptosis through TNFR1 in the already TRAF2 depleted and thus sensitized cells (Vercammen et al., 1995; Grell et al., 1999; Schneider et al., 1999; Eliopoulos et al., 2000) .
The TRAF proteins are characterized by a carboxyterminal homology domain of about 180 amino acids and have a crucial role in TNF receptor and interleukin-1 receptor/Toll-like receptor (IL1R/TLR) signaling (Wajant et al., 2001) . The amino-terminal part of all mammalian TRAF proteins, with exception of TRAF1, consists of a single RING-finger domain followed by five or seven evenly spaced zinc-finger motifs (Wajant et al., 2001) . TRAFs interact with a huge number of proteins and consequently act as scaffold proteins, organizing receptor associated as well as cytosolic signaling complexes (Wajant et al., 2001) . Deletion mutagenesis has clearly shown that the amino-terminal RING/zinc-finger domain of TRAF proteins is responsible for transmission of signals leading to the activation of NFkB and mitogen-activated protein kinase cascades or to generation of reactive oxygen species (Wajant et al., 2001) . It has been shown for TRAF2 and TRAF6 that the crucial role of their RING domain in NFkB and JNK activation is related to their capability to act as E3 ubiquitin ligases (Chen 2005) . As TRAF1 can interact with TRAF2 and as it lacks a RING/zinc-finger domain, TRAF1 has been suggested to function as a negative regulator of TRAF2-dependent signaling pathways. In fact, TRAF1 can inhibit CD40 as well as IL1 signaling and TRAF1-deficient T cells exerted increased proliferation after activation of the T-cell receptor or TNFR2 stimulation (Carpentier and Beyaert, 1999; Tsitsikov et al., 2001; Fotin-Mleczek et al., 2004) . However, with respect to the effects of TRAF1 expression on TNF-induced NFkB activation contradictory results have been reported Carpentier and Beyaert, 1999) . There is further evidence that TRAF1 acts in concert with TRAF2 to suppress TNF-induced caspase-8 activation and transgenic mice overexpressing TRAF1 exerted reduced antigen-induced apoptosis of CD8( þ ) T cells (Speiser et al., 1997) . The complex effects related to TRAF1 might be at least partially caused by the capability of this molecule to differentially regulate the interaction of TRAF2 with TRAF2-interacting receptors (Fotin-Mleczek et al., 2004) . The fact that TRAF1 not only regulates activation of NFkB and apoptosis, but also is itself regulated by these pathways, might further contribute to the puzzling effects reported for TRAF1. So, TRAF1 is induced through the NFkB pathway, but can also be specifically cleaved by caspase-8 under release of a fragment that acts as a global inhibitor of NFkB activation (Wang et al., 1998; Schwenzer et al., 1999; Irmler et al., 2000; Henkler et al., 2003) .
Here, we show that TRAF1 expression attenuates TNFR2-induced TRAF2 depletion and the herewith associated inhibition of TNFR1-induced NFkB signaling. Further, we found that TRAF1, which lacks RINGfinger domain and any enzymatic activity, co-recruits with TRAF2 to TNFR1 without affecting proinflammatory signaling by this receptor. Moreover, TRAF1 enhances TNFR2-induced NFkB activation. Thus, we identified TRAF1 as a regulator of the TNFR1-TNFR2 crosstalk and as a mediator of TNFR2 signaling.
Results
TRAF2 depletion affects function and composition of the TNFR1 signaling complex Using TNFR2 transfected Jurkat and HeLa cells, we and others have observed that TNFR2 stimulation not only results in depletion of cytoplasmic TRAF2 and enhancement of TNFR1-induced cell death, but also inhibits TNFR1-induced activation of JNK and NFkB (Chan and Lenardo, 2000; Fotin-Mleczek et al., 2002; Li et al., 2002; Wu et al., 2005 and Figures 1a and b) . To verify that TNFR2 elicits these effects also in non-transfected and primary cells, we analysed Colo205 cells and primary T cells both displaying significant expression of endogenous TNFR2. Similar to HeLa-TNFR2 transfectants, Colo205 cells prestimulated through TNFR2 displayed enhanced TNFR1-mediated cell death (Figure 1a ). TNFR1 further induced in both cell lines rapid (3 min) phosphorylation of IkBa and total disappearance of this protein within 10 min, both hallmarks of robust activation of the NFkB pathway (Hoffmann et al., 2006) . In accordance with the known NFkB dependency of the IkBa gene, IkBa levels were restored after 2 h (Figure 1b) . In TNFR2-prestimulated cells, TNFR1-induced IkBa phosphorylation was reduced and delayed and there was, further, only an incomplete disappearance of IkBa (Figure 1b) . Thus, prestimulation of TNFR2 inhibited TNFR1-mediated (Figure 1b) . Moreover, T cells obtained from three independent peripheral blood mononuclear cell samples responded with delayed and reduced IkBa phosphorylation to TNFR1 activation on TNFR2 prestimulation (Figure 1c) . Together, these data opened the possibility that TNFR2-mediated TRAF2 depletion affects the efficiency of TNFR1 signaling complex formation. As TRAF2-expression levels (50 000-200 000 molecules per cell) exceed TNFR1-cell surface expression (500-3000 molecules per cell) about two orders of magnitude, it was unclear, however, whether TRAF2 depletion after TNFR2 stimulation was efficient enough to affect the TNFR1-TRAF2 stoichiometry within the TNFR1 signaling complex. We therefore directly investigated formation of TNFR1 signaling complexes in TNFR2 prestimulated and untreated control cells. In these experiments, HeLa-TNFR2 transfectants were stimulated for 6 h with a TNFR2-selective agonist. It was then tested, how this prestimulation of TNFR2 affects the signaling functions of TNFR1. To obtain TNFR1 and TNFR2 immunoprecipitates from the same sample, we used a Fc-fusion protein of the TNFR2-specific TNF mutant 143N/145R and the Flag-tagged TNFR1-specific TNF mutant 32W/ 86T for receptor stimulation. These reagents allowed sequential immunoprecipitation of the respective TNFreceptor signaling complexes with protein G agarose and anti-Flag mAb M2 agarose. In accordance with the overall reduction in TRAF2 expression levels observed after TNFR2 stimulation, we found a significant decrease in the amount of TNFR1-bound TRAF2 in TNFR2-prestimulated cells (Figure 1d , lane 5 and 6 of anti-Flag IP). Moreover, occurrence of slower migrating RIP species and recruitment of IKK1, both indicative for an NFkB-stimulating TNFR1 signaling complex (Legler et al., 2003) , were also significantly reduced ( Figure 1d , lane 5 and 6 of anti-Flag IP). Recruitment of TRADD, however, remained unchanged ( Figure 1d ). Thus, TNFR2-induced depletion of TRAF2 affected function and composition of the TNFR1 signaling complex downstream of TRADD.
TRAF1 expression does not interfere with TNFR1 signaling despite reducing TRAF2 recruitment to the TNFR1 signaling complex TRAF1 is known to form heteromeric complexes with TRAF2 . We therefore asked whether this molecule regulates signaling by TNFR1 and TNFR2. TRAF1 was not, or, only very weakly detectable in lysates ( Figure 2a ) and TNF receptor immunoprecipitates (Figures 2b and c) of HeLa-TNFR2 and Colo205 cells. However, TRAF1 is upregulated in HeLa and Colo205 cells through the NFkB pathway ( Figure 2a and Schwenzer et al., 1999) . Putative regulatory functions of TRAF1 should therefore become especially apparent after its transcriptional induction. As upregulation of TRAF1 by stimulation of the NFkB pathway would interfere with the analysis of TNF receptor signaling because of the concomitant upregulation of NFkB regulatory factors (for example, A20, CYLD) and antiapoptotic proteins (for example, FLIP, Bcl2, cIAP2), we decided to analyse the effect of TRAF1 in HeLa-TNFR2 and Colo205 cells, in which TRAF1 was stably expressed (Figure 2a ). To rule out that observed TRAF1 effects on TNFR1 and TNFR2 are caused by non-physiological TRAF1 concentrations, we screened individual clones derived from TRAF1 transfected HeLa-TNFR2 and Colo205 cell populations for 'physiological' TRAF1 expression. We choose one clone of each cell population (Colo205-TRAF1, HeLa-TNFR2-TRAF1), which showed comparable or even lower TRAF1 expression than a panel of cell lines with constitutive TRAF1 expression ( Figure 2a ). In fact, the TRAF1 expression levels of the clones used were comparable to those induced by TNF in the corresponding parental cell lines ( Figure 2a ). Immunoprecipitation of the TNFR1 signaling complex from these TRAF1 transfectants and corresponding vector-transfected control cells (Colo205-vec; HeLa-TNFR2-vec) showed that TRAF1 recruits to TNFR1 without interfering with RIP modification or IKK1 recruitment (Figures 2b and c) . In fact, recruitment of the latter was rather enhanced in TRAF1 expressing cells. However, the amount of TRAF2, which was recruited into the TNFR1 signaling complex in TRAF1 expressing cells, was partially reduced. Likewise, TRAF1 was efficiently recruited to TNFR2, whereas TRAF2 recruitment was somewhat reduced compared with vector transfected control cells (Figures 2b and c) . Together, these data suggest that TRAF1 can substitute for TRAF2 in TNFR1 and TNFR2 signaling complex formation. In accordance with the 'normal' appearance of the TNFR1 signaling complex in TRAF1 expressing cells, TNFR1-induced phosphorylation of IkBa and TNFR1-induced IL8 production were not significantly altered (Figures 3a-c).
TRAF1 expression enhances TNFR2-induced NFkB activation and IL8 production Although TNFR2 is much higher expressed on the cell surface than TNFR1 in HeLa-TNFR2 and Colo205 cells, TNFR1 activation resulted in an approximately fivefold higher production of the NFkB target IL8. This is in good accordance with the known weak ability of TNFR2 to activate NFkB in many cells . It is noted that in the TRAF1 transfectants, TNFR2-induced production of IL8, a prominent NFkB target, was significantly increased (Figure 3a) . Moreover, IkBa phosphorylation was accelerated and IkBa degradation was enhanced on TNFR2 stimulation in the TRAF1 expressing cells (Figure 3d ). Together, these data indicate enhanced activation of the NFkB pathway by TNFR2 in TRAF1 expressing cells.
TRAF1 expression antagonizes depletion of cytosolic TRAF2 and inhibition of TNFR1 signaling by TNFR2 From Figure 1d , it was already evident that stimulation of TNFR2 in HeLa-TNFR2 cells results in a strong TRAF1 regulates TNFR2 signaling A Wicovsky et al reduction of the TRAF2 concentration in the triton X 100 soluble fraction after 6 h. The same was observable in Colo205 cells (Figure 4a) . Concomitantly, the concentrations of total TRAF2 were only slightly diminished in TNFR2-stimulated cells (Figures 4a and  b) . Inhibition of the proteasome had no, or, only a minor effect on depletion of TRAF2 from the triton X 100 soluble fraction, but fully rescued TRAF2 expression in the total lysates (Figures 4a and b) . It is noted that TNFR2-induced depletion of TRAF2 from the triton X 100 soluble fraction was significantly reduced in the HeLa-TNFR2-TRAF1 and Colo205-TRAF1 cells . Together, these data confirm our earlier findings showing that TRAF2 depletion from the triton X 100 soluble pool without proteasomal degradation is already sufficient to inhibit TNFR1-induced NFkB activation . More important, our data suggest that TRAF1 expression interferes with TNFR2-induced TRAF2 depletion/ degradation by retaining it in the triton X 100 soluble fraction. In fact, several studies have shown that proteasomal degradation of TRAF2 occurs in a triton X 100 insoluble lipid raft-related compartment (Brown et al., 2002; Fotin-Mleczek et al., 2002; Wu et al., 2005) . We next analysed Colo205 cells with respect to the role of TRAF1 in the TNFR1-TNFR2 crosstalk. In accordance with the protective effect of TRAF1 on TRAF2, inhibition of Fc-TNF(32W/86T)-induced NFkB and JNK activation by TNFR2 prestimulation was clearly less strong in Colo205-TRAF1 cells compared with Colo205-vec cells (Figure 5a ). Thus, TNFR1-induced phosphorylation and degradation of IkBa was increased in TNFR2-primed Colo205-TRAF1 cells compared with TNFR2-primed Colo205-vec cells. The relief of proinflammatory TNFR1 signaling from TNFR2-mediated inhibition corresponded with improved TNFR1 signaling complex formation. Thus, TNFR1-associated RIP ubiquitination and IKK1 recruitment, which were strongly impaired in TNFR2-prestimulated Colo205-vec cells, were increased in the Colo205-TRAF1 cells (Figure 5b ). Taken together, these data show that TRAF1 liberates TNFR1 from the control of TNFR2 by preventing TNFR2-induced translocation of TRAF2 into a triton X 100 insoluble 'compartment'.
Discussion
TRAF1 is a prototypic target of the classical NFkB pathway. Remarkably, TRAF1 strongly interacts with TRAF2, which is a pivotal mediator of NFkB activation by various members of the TNF receptor family including TNFR1 . We observed that TRAF1 co-recruits with TRAF2 into the TNFR1 signaling complex (Figures 2b and c) . It is noted that we found no interference of TNFR1-associated TRAF1 with TRAF2-dependent TNFR1 signaling, despite diminishing concomitant TRAF2 recruitment into the TNFR1 signaling complex (Figures 2b,c and 3a,b) . This observation was not trivial as in contrast to TRAF2, TRAF1 lacks a RING/zinc-finger effector domain with E3 ligase activity, which is critically involved in TNFinduced activation of NFkB and JNK (Habelhah et al., 2004) . It appears therefore possible that TRAF1 functionally substitutes for TRAF2 in TNFR1 signaling, at least as long as it is part of a heteromeric complex with TRAF2. This concept seems especially appealing in light of the recent finding that cIAP1 and cIAP2, which both efficiently interact with TRAF1 and TRAF2, are essentially involved in TNF-induced RIP ubiquitination and NFkB activation (Mahoney et al., 2008) .
TNFR2 stimulation results in translocation of TRAF2 into a triton X 100 insoluble fraction, widely accepted as lipid raft fraction (Figure 4 ; Fotin-Mleczek et al., 2002; Wu et al., 2005) . TRAF1 attenuates the corresponding drop in cytoplasmic available TRAF2 and enhances TNFR2-induced NFkB signaling (Figure 3d ). It is therefore tempting to speculate that enhanced TNFR2-induced NFkB signaling is because of TRAF1-mediated preservation of cytoplasmic TRAF2. However, this is most likely not the only TRAF1-related effect contributing to enhanced TNFR2-mediated NFkB activation. In fact, TNFR2-induced translocation of TRAF2 into the triton X 100 insoluble fraction was earliest evident after 2 h and requires several hours to become clearly visible (Figure 1 and Fotin-Mleczek et al., 2002), whereas enhanced TNFR2-induced phosphorylation of IkBa in TRAF1 expressing cells occurred already after a few minutes (Figure 3d ). It appears therefore possible that heteromeric TRAF1-TRAF2 complexes are superior to TRAF2 homomeric complexes in mediating TNFR2-induced NFkB activation. It has been recently reported that TNFR2 stimulation also triggers protein degradation of the p38 and JNK activating mitogen-activated protein-3K apoptosis signaling kinase-1 (Zhao et al., 2007) . It is therefore possible that the enhanced TNFR2-induced IL8 production in TRAF1 expressing cells is not only caused by Colo205 cells and HeLa-TNFR2 transfectants (a and b) were stimulated with an oligomerized preparation of the Flag-tagged TNFR2-specific TNF mutant 143N/145R (200 ng/ml) for 6 h. Then TNFR1 signaling was either specifically triggered overnight with the indicated concentrations of Fc-TNF(32W/86T) in the presence of 2.5 mg/ml cyclohexemide to induce cell death (a) or stimulated for the indicated times with 50 ng/ml of Fc-TNF(32W/86T) to analyse activation of NFkB and JNK (b). TNFR1-induced cell death was determined by crystal violet staining. To monitor activation of the NFkB and JNK pathway, cell lysates were subjected to western blot analysis, using antibodies recognizing phospho-JNK, the activated form of JNK, phospho-IkBa, indicative for activation of the IKK complex, and IkBa allowing to follow the degradation of this protein. Detection of total JNK and tubulin served as loading controls. Lysates were also probed for the presence of TRAF2. (c) T cells isolated from three different donors were activated with PHA (5 mg/ml) and IL2 (20 U/ml) for 8 days. TNFR2-primed (6 h, 200 ng/ml oligomerized TNF(143N/145R)) and non-primed T cells were then challenged for the indicated times with 200 ng/ml Fc-TNF(32W/86T). Finally, IkBa and phospho-IkBa were again detected by western blotting. Tubulin and p42/44 served as loading controls. (d) HeLa-TNFR2 cells were selectively stimulated with a mixture of 600 ng/ml of a Fc-fusion protein of TNF(143N/145R) and 1 mg/ml of the TNFR2-specific antibody 80M2 (lanes 4 and 6). One TNFR2 prestimulated group and untreated cells were then challenged for 20 min with 400 ng/ml of the TNFR1-specific ligand Flag-TNF(32W/ 86T) (lane 5 and 6). The TNFR2 and TNFR1 signaling complexes were sequentially isolated using protein G agarose and anti-Flag mAb M2 agarose. Immunoprecipitates and lysates were then analysed with antibodies recognizing the indicated proteins. Lysates of untreated cells supplemented with buffer (lane 1) or a mixture of 50 ng Fc-TNF(143N/145R) and 100 ng 80M2 (lane 2) or 60 ng Flag-TNF(32W/86T) (lane 3) were immunoprecipitated as controls.
TRAF1 regulates TNFR2 signaling A Wicovsky et al inhibition of TRAF2 depletion and enhanced NFkB signaling, but maybe also by blocking degradation of apoptosis signaling kinase-1.
We and others have shown in recent years that TNFR2 stimulation boosts/enhances TNFR1-dependent apoptosis Murray TRAF1 regulates TNFR2 signaling A Wicovsky et al latter on TNFR1 signaling complex formation has not been investigated so far. Here, we give evidence that TNFR2-induced translocation of TRAF2 from the triton X 100 soluble cytosolic fraction to a triton X 100 insoluble compartment (Figure 4 ) results, indeed, in reduced availability of TRAF2 for formation of the TNFR1 signaling complex (Figures 1d and 5b) . Moreover, the reduced recruitment of TRAF2 into the TNFR1 signaling complex was accompanied with a drop in TRAF2-related functions in the TNFR1 signaling complex. Thus, RIP ubiquitination and IKK1 recruitment, which are dependent on TRAF2 (Lee et al., 2004) , were also diminished (Figures 1d and  5b) . It is noted that TRAF1 expression antagonizes TNFR2-induced depletion of TRAF2 and its subsequent proteasomal degradation (Figure 4 ). This is reminiscent to CD40 signaling in dendritic cells, where TRAF1 expression prevented receptor-induced recruitment of TRAF2 into lipid rafts (Arron et al., 2002) . Accordingly, TRAF1 expression also partly rescued The next day cells were stimulated in triplicates with increasing concentrations of the TNFR1-specific mutant Flag-TNF(32W/86T) or oligomerized, TNFR2-specific Flag-scTNF(143N/145R). After 6 h supernatants were collected and analysed by ELISA for their IL8 content. Cell culture medium was changed before stimulation to minimize the background that is caused by constitutive IL8 expression. (c and d) For analysis of the activation of the NFkB pathway the various cell lines were challenged with 50 ng/ml Fc-TNF(32W/86T) or 50 ng/ml oligomerized Flag-scTNF(143N/145R) for the indicated times. Whole cell lysates were subjected to western blot analysis using antibodies recognizing phospho-IkBa, IkBa and tubulin as a loading control.
TRAF1 regulates TNFR2 signaling
A Wicovsky et al TNFR1-mediated activation of NFkB and JNK in TNFR2-prestimulated Colo205 cells ( Figure 5 ). To show the regulatory effects of TRAF1 on TNFR2-induced TRAF2 depletion/degradation and TNFR1 signaling, we used in our study artificial, but clearly defined experimental conditions (independent activation of TNFR1 and TNFR2 by the use of TNF receptorspecific mutants; TNFR2 'priming') to facilitate interpretation of the experimental data. This raises the question asking for the physiological conditions under which our findings become relevant. Whether a TNFR1-TNFR2 coexpressing cell encounters an environment where only soluble TNF is present, there is practically exclusive TNFR1 activation and the regulatory mechanisms described in this study gain no relevance. However, if there are membrane TNF expressing cells present in the vicinity or whether there is induction of endogenous membrane TNF, the cell will experience costimulatory conditions (Figure 6 , left part of the model). At the beginning, TNFR2-induced degradation/depletion of TRAF2 has limited relevance in this scenario, as TNFR1-induced activation of NFkB is faster than TRAF2 depletion . However, TNFR1 is rapidly internalized and over time ongoing TNFR1 activity will significantly depend on the stimulation of new receptor molecules appearing at the plasma membrane. These secondarily stimulated TNFR1 molecules will now find a situation, where TRAF2 has already been degraded, thus 'TNFR2 prestimulated' conditions ( Figure 6 , right part of model). The complexity of TNFR1-TNFR2 signaling under these conditions is then further increased by the fact that TNFR2-induced TRAF2 degradation occurs temporally parallel to upregulation of the TRAF2-protective TRAF1 molecule because of earlier triggered TNFR1 (Figure 6 ). Moreover, if endogenous membrane TNF is induced, TRAF1 might further promote its own production by enhancing TNFR2-induced NFkB signaling. Thus, the regulatory effects of TRAF1 on TNFR1 and TNFR2 signaling, as described in our study, become, under physiological conditions especially important when a cell is either durable exposed to TNF or whether a cell itself produces TNF over a longer period of time. The mechanisms discussed in the model shown in Figure 6 are certainly not the only ones describing the long-term behavior of cells in a TNF receptor stimulating environment, but might act in concert with other mechanisms, such as receptor shedding and induction of additional factors involved in the regulation of apoptosis and NFkB .
The regulatory mechanisms summarized in Figure 6 are possibly of special relevance in T cells and macrophages as these cell types express both TNF receptors and are major producers of TNF . Particularly, chronic activation of these cells is of great significance in TNF-driven autoimmune diseases, such as rheumatoid arthritis and Crohn's disease. In course of an immune reaction, activation of immune cells is accompanied by activation of the NFkB TRAF1 regulates TNFR2 signaling A Wicovsky et al pathway and there is evidence that downregulation of peripheral T cells involves TNF-induced apoptosis (Zheng et al., 1995; Speiser et al., 1996) . Further studies have to show whether TRAF1, which is upregulated in course of macrophage and/or T-cell activation, delivers a transient protection against apoptosis induction by cooperative TNFR1-TNFR2 signaling. In accordance with this hypothesis, it has been reported that T cells from TRAF1 transgenic mice were protected against apoptosis (Speiser et al., 1997) . 6 h TNFR2 prestimulation 6 h TNFR2 prestimulation 6 h TNFR2 prestimulation 6 h TNFR2 prestimulation Figure 5 The inhibitory effect of TNFR2 activation on proinflammatory TNFR1 signaling is diminished in the presence of TRAF1. (a) Colo205-vec and Colo205-TRAF1 cells were pre-stimulated with 200 ng/ml oligomerized Flag-scTNF(143N/145R) for 6 h or remained untreated. For analysis of the activation of the NFkB and JNK pathway cells were challenged with 50 ng/ml Fc-TNF(32W/ 86T) for the indicated times and cell lysates were subjected to western blot analysis using antibodies recognizing phospho-JNK, phospho-IkBa, JNK, IkBa and tubulin as a loading control. (b) Colo205-vec and Colo205-TRAF1 cells were stimulated with oligomerized Flag-scTNF(143N/145R) for 6 h or remained untreated. Cells were then stimulated for the indicated times with 200 ng/ml Fc-TNF(32W/86T) and the TNFR1 signaling complexes were isolated using protein G agarose beads. Immunoprecipitates together with the corresponding lysates were analysed with antibodies recognizing the indicated proteins. Lysates of untreated and TNFR2-primed cells supplemented with 50 ng Fc-TNF (32W/86T) were immunoprecipitated as controls.
Materials and methods
Cell lines, reagents and antibodies HeLa, Colo205 and HEK293 cells were maintained in RPMI 1640 medium (PAA, Pasching, Germany), containing 10% heat inactivated fetal calf serum. The HeLa population stably overexpressing TNFR2 (HeLa-TNFR2) has been described elsewhere . The TNF mutations conferring specificity for TNFR1 (32W/86T) and TNFR2 (143N/145R) have been originally described by Loetscher et al. (1993) . Dependent on the experiment TNFR1-specific TNF was used as a Flag-tagged variant (Flag-TNF(32W/86T)) or as a fusion protein with the constant region of human immunoglobulin G1 (Fc-(32W/86T)). The TNFR2-specific TNF mutant was expressed in form of a Flag-tagged single chain trimer (Flag-scTNF(143N/145R) ). Thus, three TNF domains representing soluble TNF monomers were fused by genetic engineering using two short peptide linkers (Krippner-Heidenreich et al., 2008) . In contrast to a His-tagged version of this molecule (Krippner-Heidenreich et al., 2008) heterotrimerization of TNF domains of different single chain TNF molecules of Flag-scTNF(143N/145R) was observed. This results in oligomerization of ligand trimers. In contrast to soluble TNF(143N/145R) trimers, the corresponding oligomers display high activity on TNFR2 (data not shown). In experiments, in which TNFR1 and TNFR2 were immunoprecipitated from the same sample, the TNFR2-specific TNF mutant was used in form of a Fc-fusion protein (Fc-TNF(143N/145R)) to avoid interference with the anti-Flag immunoprecipitation with Flag-TNF(32W/86T). MG132 was purchased from Calbiochem (Schwalbach, Germany). Cyclohexemide, anti-Flag mAb M2 agarose and protein G agarose beads were obtained from Sigma (Deisenhofen, Germany). Antibodies specific for JNK, phospho-JNK and phosphoIkBa were purchased from Cell Signaling (Beverly, MA, USA). IkBa-, TNFR1-, TNFR2-, TRAF1-, TRAF2-specific antibodies were obtained from Santa Cruz (Santa Cruz, CA, USA), anti-RIP and anti-IKK1 were from BD Biosciences Pharmingen (Heidelberg, Germany) and anti-tubulin was from Dunn Labortechnik (Asbach, Germany).
Retroviral infection
TRAF1 encoding cDNA was cloned into the retroviral vector pLZNGFR-PKG (kind gift of Dr Max Topp, University of Wu¨rzburg, Germany) placing TRAF1 under control of the PKG promotor. Upstream of the mouse PKG promotor a truncated version of the human low-affinity NGFR is expressed by the 5 0 long terminal repeat of the vector to facilitate enrichment of infected cells. The retroviral TRAF1 construct was transfected into the Phoenix-GALV packing cell line using lipofectamine (Invitrogen, Karlsruhe, Germany). After 7-10 days virus particle-containing supernatants were harvested from puromycin-resistant cells and stored at À80 1C until use. After filtration (0.4 mm) supernatants were added to Colo205 and HeLa-TNFR2 cells and centrifuged for 3 h at 21 1C in the presence of 1 mg/ml polybrene. After additional 7 days cells were analysed for NGFR expression by FACS and thereafter immunoselected with NGFR beads (Milteny TRAF1 regulates TNFR2 signaling A Wicovsky et al Biotech, Bergisch-Gladbach, Germany). Finally, individual clones were obtained by limited dilution and screened for 'physiological' expression levels of TRAF1 by western blotting.
Cell death assay Cells (20 Â 10 3 ) were seeded in 96-well plates. The next day, cells were challenged with indicated mixtures of TNF receptorspecific TNF variants in the presence of cyclohexemide (2.5 mg/ ml). Cell viability was determined after 16 h by crystal violet staining.
Determination of IL8 production Cells (20 Â 10 3 ) were seeded in triplicates in 96-well tissue culture plates and cultured overnight. The following day, medium was changed and cells were incubated for 6 h with the indicated concentrations of TNF(32W/86T) or oligomerized TNF(143N/145R). Finally, supernatants were collected and IL8 was quantified by enzyme-linked immunosorbent assay (BD Biosciences Pharmingen, Heidelberg, Germany).
Western blotting and coimmunoprecipitation
For detection of phosphorylated proteins cells were harvested into ice-cold phosphate buffered saline, collected by centrifugation and then directly lysed in 4 Â Laemmli sample buffer (8% sodium dodecyl sulfate, 0.1 M dithiothreitol, 40% glycerol, 0.2 M Tris, pH 8.0) supplemented with phosphatase inhibitor cocktails I and II (Sigma). After sonification (10 pulses) protein samples were boiled for 5 min at 96 1C, separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to nitrocellulose membranes. After blocking of non-specific binding sites by incubation in Tris-buffered saline containing 0.1% Tween 20 and 5% dry milk, western blot analyses were performed with primary antibodies of the indicated specificity, horseradish peroxidase-conjugated secondary antibodies (Dako, Hamburg, Germany) and the ECL western blotting detection reagents and analysis system (Amersham Biosciences, Muenchen, Germany). In the immunoprecipitation experiments one confluent 175-cm 2 flask of HeLa or Colo205 cells was used per condition. Briefly, cells were treated for 60 min on ice with 10 ml medium containing the indicated TNF variant or left untreated. Subsequently, the temperature was shifted to 37 1C for the indicated times. Cells were washed twice with ice-cold phosphate buffered saline and lysed with 1 ml lysis buffer (30 mM Tris-HCl, pH 7.5, 1% Triton X 100, 10% glycerol, 120 mM NaCl) supplemented with complete protease inhibitor cocktail (Roche Diagnostics GmbH, Mannheim, Germany) for 20 min on ice. Lysates were centrifuged twice (5 min, 5000 g; 20 min, 14 000 g) and the TNF receptor complexes were precipitated from the cleared lysate with protein G agarose beads (40 ml of a 50% slurry) or anti-Flag mAb M2 agarose beads (60 ml of a 50% slurry) at 4 1C overnight. As a negative control, lysates from unstimulated cells were supplemented with 60 ng of the corresponding TNF variant. The precipitates were washed five times with ice-cold lysis buffer, and bound proteins were eluted by incubation at 75 1C for 10 min in 4 Â Laemmli sample buffer. For sequential immunoprecipitation of TNFR1 and TNFR2 from the same sample, we used Flag-TNF(32W/86T) and a mixture of Fc-TNF(143N/145R) and the TNFR2-specific mAb 80M2. The two different TNF variants were then sequentially immunoprecipitated with M2 agarose and protein G agarose beads. Whether only TNFR1 or TNFR2 was immunoprecipitated, we used Fc-TNF(32W/ 86T) and protein G agarose or Flag-scTNF(143N/145R) and M2 agarose.
Isolation and activation of primary T cells Peripheral blood mononuclear cells were isolated by Ficoll (PAA, Pasching) density-gradient centrifugation from cells retained in leukoreduction system chambers (Dietz et al., 2006) . T cells were isolated with a MACS Seperator using CD3-specific beads (Milteny Biotech, Auburn, CA, USA). The purity of isolated T cells was verified by flow cytometry analysis using a CD3-specific antibody (Milteny). Activated T cells were generated by stimulation with phytohemagglutinin (PHA) (5 mg/ml) (Sigma) and IL2 (20 U/ml) (Chiron, Mu¨nchen, Germany) for 8 days.
